Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reactions
Research from University of Toronto provides new data on adverse drug reactions
June 3rd, 2008
"Sorafenib, an oral multikinase inhibitor, prolonged progression-free survival when compared with placebo, as second-line therapy for patients with metastatic renal carcinoma (MRC). Grade 3/4 adverse events were reported in 12% of patients," scientists in Toronto, Canada report. "This study presents sorafenib's efficacy and safety in a less selected cohort of patients enrolled in an expanded access program. Patients with MRC received sorafenib 400 mg twice daily until disease progression. Tumor response was evaluated by RECIST criteria. Adverse events were graded by NCI common toxicity criteria. From November 2005 to August 2006, 58 patients were enrolled. The median...
Source: Cancer Weekly (2008-06-03)
|
